Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

By Jie Yang, R. Sherry, S. Steinberg, S. Topalian, D. Schwartzentruber, P. Hwu, C. Seipp, Linda J. Rogers-Freezer, K. Morton, D. White and 3 more. Journal of Clinical Oncology, 2003

809 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e30d68cc2e4bcf722ce4cd1783dd2cbd57413bb5

Citations in the corpus

• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. (2005, neutral): “In 2003, NCI Surgery Branch investigators reported results of a randomized phase III trial that compared the efficacy and toxicity of HD IV IL-2 to a lower-dose IV regimen (10% of high dose) using an otherwise identical administration schedule.(18) In that study, patients who received HD IL-2 had a ”